Protalix BioTherapeutics (PLX) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 26, 2025, in Tel Aviv, with voting on director elections, executive compensation, and auditor ratification.

• Shareholders of record as of April 30, 2025, are eligible to vote, with 79,517,147 shares outstanding.

• Voting can be done by mail, Internet, telephone, or in person, and a quorum requires at least one-third of shares present or represented.

• Proxy solicitation is managed by Alliance Advisors LLC, with estimated costs of $35,000.

Voting matters and shareholder proposals

• Proposals include electing or re-electing eight directors, an advisory vote on executive compensation, and ratification of Kesselman & Kesselman as independent auditor for 2025.

• Board recommends voting FOR all director nominees, FOR executive compensation, and FOR auditor ratification.

• Shareholder proposals for the 2026 meeting must be submitted by January 1, 2026, with specific disclosure requirements.

Board of directors and corporate governance

• Eight director nominees, including one new nominee, with diverse backgrounds in biotech, finance, and business development.

• Majority of board members are independent per NYSE American and SEC standards.

• Board committees include Audit and Finance, Compensation, and Nominating, all with independent members.

• Chairman role is separate from CEO, and non-management directors meet at least twice per year.